We could not find any results for:
Make sure your spelling is correct or try broadening your search.
based pharmaceuticals firm - Says Dreamm-7 trial shows sustained overall survival benefit for Blenrep, the brand name ...
GSK PLC 09 December 2024 Issued: 9 December 2024, London UK Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first...
GSK PLC on Monday received a double-dose of good news with its Nucala and Blenrep products receiving positive indicat ...
GSK PLC 09 December 2024 Issued: 9 December 2024, London UK Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma ●...
GSK PLC 09 December 2024 Issued: 09 December 2024 London UK US FDA accepts GSK's submission for the use of Nucala (mepolizumab) in COPD · Submission supported by MATINEE data showing...
GSK PLC on Thursday said it has expanded its shingles vaccine collaboration with Chongqing Zhifei Biological Products ...
GSK PLC 05 December 2024 Issued: 5 December 2024, London UK GSK and Zhifei revise and extend strategic vaccine collaboration in China · Shingrix collaboration extended to 2034 · ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -11.5 | -0.854700854701 | 1345.5 | 1398 | 1330 | 9172210 | 1352.57459281 | DE |
4 | -19.5 | -1.44070927226 | 1353.5 | 1398 | 1282.5 | 8924793 | 1335.00495925 | DE |
12 | -271.5 | -16.9106197446 | 1605.5 | 1608.5 | 1282.5 | 8676700 | 1417.58491169 | DE |
26 | -280 | -17.3482032218 | 1614 | 1678 | 1282.5 | 7705116 | 1492.17346926 | DE |
52 | -118.2 | -8.13937474177 | 1452.2 | 1820 | 1282.5 | 7949606 | 1561.98026727 | DE |
156 | -273.8 | -17.0294812788 | 1607.8 | 1824.4 | 1282.5 | 8642754 | 1528.78819921 | DE |
260 | -418.2 | -23.8671384545 | 1752.2 | 1857 | 1190.8 | 8825335 | 1510.47759033 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions